Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Secondary Malignancy
Conditions: Non-Hodgkin Lymphoma; Chronic Lymphocytic Leukaemia; Multiple Myeloma Interventions: Biological: Idecabtagene vicleucel; Biological: Lisocabtagene maraleucel Sponsors: Bristol-Myers Squibb Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer & Oncology | Chronic Leukemia | Chronic Lymphocytic Leukemia | Genetics | Leukemia | Lymphoma | Myeloma | Non-Hodgkin's Lymphoma | Research